Anchor Investment Management LLC Sells 68 Shares of Becton, Dickinson and Company (NYSE:BDX)

Anchor Investment Management LLC decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 7.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 868 shares of the medical instruments supplier’s stock after selling 68 shares during the period. Anchor Investment Management LLC’s holdings in Becton, Dickinson and Company were worth $203,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of BDX. First Trust Advisors LP boosted its stake in shares of Becton, Dickinson and Company by 880.8% during the 4th quarter. First Trust Advisors LP now owns 294,082 shares of the medical instruments supplier’s stock valued at $71,706,000 after purchasing an additional 264,097 shares in the last quarter. 1832 Asset Management L.P. boosted its stake in Becton, Dickinson and Company by 23.7% during the fourth quarter. 1832 Asset Management L.P. now owns 43,629 shares of the medical instruments supplier’s stock worth $10,638,000 after acquiring an additional 8,373 shares in the last quarter. Cibc World Markets Corp boosted its stake in Becton, Dickinson and Company by 133.2% during the fourth quarter. Cibc World Markets Corp now owns 37,341 shares of the medical instruments supplier’s stock worth $9,105,000 after acquiring an additional 21,329 shares in the last quarter. Stephens Inc. AR boosted its stake in Becton, Dickinson and Company by 21.5% during the fourth quarter. Stephens Inc. AR now owns 16,698 shares of the medical instruments supplier’s stock worth $4,072,000 after acquiring an additional 2,953 shares in the last quarter. Finally, Epoch Investment Partners Inc. boosted its stake in Becton, Dickinson and Company by 8.0% during the fourth quarter. Epoch Investment Partners Inc. now owns 14,755 shares of the medical instruments supplier’s stock worth $3,598,000 after acquiring an additional 1,095 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.4 %

Shares of Becton, Dickinson and Company stock opened at $238.22 on Friday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.36 and a current ratio of 1.85. The stock has a market capitalization of $68.85 billion, a PE ratio of 52.47, a price-to-earnings-growth ratio of 1.92 and a beta of 0.42. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $269.52. The company has a 50-day simple moving average of $236.66 and a two-hundred day simple moving average of $235.59.

Becton, Dickinson and Company (NYSE:BDX) last issued its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analysts’ expectations of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.96 earnings per share. On average, analysts anticipate that Becton, Dickinson and Company will post 13.1 EPS for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 30th. Stockholders of record on Monday, September 9th were issued a dividend of $0.95 per share. The ex-dividend date was Monday, September 9th. This represents a $3.80 annualized dividend and a dividend yield of 1.60%. Becton, Dickinson and Company’s payout ratio is 83.70%.

Analyst Ratings Changes

BDX has been the topic of several research reports. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Evercore ISI boosted their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday. Stifel Nicolaus boosted their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Finally, Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and boosted their price objective for the stock from $255.00 to $275.00 in a research note on Tuesday. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Becton, Dickinson and Company currently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.